1030633-41-0Relevant academic research and scientific papers
New solid forms of the anti-HIV drug etravirine: Salts, cocrystals, and solubility
Rajput, Lalit,Sanphui, Palash,Desiraju, Gautam R.
, p. 3681 - 3690 (2013)
Thirteen new solid forms of etravirine were realized in the process of polymorph and cocrystal/salt screening to improve the solubility of this anti-HIV drug. One anhydrous form, five salts (hydrochloride, mesylate, sulfate, besylate, and tosylate), two cocrystals (with adipic acid and 1,3,5-benzenetricarboxylic acid), and five solvates (formic acid, acetic acid, acetonitrile, and 2:1 and 1:1 methanolates) were obtained. The conformational flexibility of etravirine suggests that it can adopt four different conformations, and among these, two are sterically favorable. However, in all 13 solid forms, the active pharmaceutical ingredient (API) was found to adopt just one conformation. Due to the poor aqueous solubility of the API, the solubilities of the salts and cocrystals were measured in a 50% ethanol-water mixture at neutral pH. Compared to the salts, the cocrystals were found to be stable and showed an improvement in solubility with time. All the salts were dissociated within an hour, except the tosylate, which showed 50% phase transformation after 1 h of the slurry experiment. A structure property relationship was examined to analyze the solubility behavior of the solid forms.
POLYMORPHS OF ETRAVIRINE AND PROCESSES FOR PREPARATION THEREOF
-
Page/Page column 16, (2010/12/17)
The present invention provides novel crystalline forms of etravirine such as forms A, B, D, E, H, J, K, L and M, pharmaceutical compositions comprising the crystalline forms and method of using at least one of the crystalline forms or pharmaceutical compositions to treat HIV.
